Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BDRXNASDAQ:FBLGNASDAQ:RPTXNASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBDRXBiodexa Pharmaceuticals$0.87-15.9%$1.27$0.78▼$41.50$37.64M1.211.09 million shs1.72 million shsFBLGFibroBiologics$0.70-3.1%$0.93$0.70▼$6.12$27.47M-0.8299,437 shs307,259 shsRPTXRepare Therapeutics$1.41$1.35$0.89▼$4.29$60.48M0.84250,767 shs60,874 shsUPXIUpexi$9.25-14.3%$10.13$1.90▼$22.57$409.11M-0.3893,017 shs2.22 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBDRXBiodexa Pharmaceuticals-15.87%-19.02%-33.35%-51.05%+86,649,900.00%FBLGFibroBiologics-3.12%-13.99%-23.85%-37.33%-88.78%RPTXRepare Therapeutics0.00%-3.89%+6.82%+25.89%-61.16%UPXIUpexi-14.27%-7.59%-27.56%+297.00%+15.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBDRXBiodexa Pharmaceuticals0.2809 of 5 stars0.03.00.00.02.40.00.0FBLGFibroBiologics3.0604 of 5 stars3.64.00.00.01.72.50.6RPTXRepare Therapeutics1.9848 of 5 stars3.33.00.00.00.02.50.6UPXIUpexi2.8417 of 5 stars3.53.00.00.02.63.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBDRXBiodexa Pharmaceuticals 0.00N/AN/AN/AFBLGFibroBiologics 3.20Buy$13.001,768.89% UpsideRPTXRepare Therapeutics 2.50Moderate Buy$4.50219.15% UpsideUPXIUpexi 3.00Buy$16.0072.97% UpsideCurrent Analyst Ratings BreakdownLatest UPXI, FBLG, RPTX, and BDRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.006/16/2025UPXIUpexiCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Overweight$16.005/15/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/9/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.004/1/2025FBLGFibroBiologicsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.00(Data available from 6/21/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBDRXBiodexa Pharmaceuticals$470K67.37N/AN/A$0.29 per share2.99FBLGFibroBiologicsN/AN/AN/AN/A$0.08 per shareN/ARPTXRepare Therapeutics$53.48M1.13N/AN/A$3.56 per share0.40UPXIUpexi$26M13.49N/AN/A$6.24 per share1.48Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBDRXBiodexa Pharmaceuticals-$7.32MN/A0.00N/AN/AN/AN/AN/A7/11/2025 (Estimated)FBLGFibroBiologics-$11.16M-$0.21N/AN/AN/AN/A-1,022.04%-117.56%8/6/2025 (Estimated)RPTXRepare Therapeutics-$84.69M-$3.01N/AN/AN/AN/A-78.12%-67.11%N/AUPXIUpexi-$23.66MN/A0.00∞N/A-135.86%-535.19%-122.94%7/8/2025 (Estimated)Latest UPXI, FBLG, RPTX, and BDRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/16/2025Q1 2025UPXIUpexiN/A-$2.87N/A-$2.87N/A$3.16 million5/13/2025Q1 2025FBLGFibroBiologics-$0.10-$0.14-$0.04-$0.14N/AN/A3/31/2025Q4 2024FBLGFibroBiologics-$0.10-$0.09+$0.01-$0.09N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBDRXBiodexa PharmaceuticalsN/AN/AN/AN/AN/AFBLGFibroBiologicsN/AN/AN/AN/AN/ARPTXRepare TherapeuticsN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBDRXBiodexa Pharmaceuticals0.011.751.75FBLGFibroBiologicsN/A1.141.14RPTXRepare TherapeuticsN/A7.427.42UPXIUpexi0.310.370.24Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBDRXBiodexa Pharmaceuticals17.51%FBLGFibroBiologicsN/ARPTXRepare Therapeutics85.09%UPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipBDRXBiodexa Pharmaceuticals0.34%FBLGFibroBiologics20.00%RPTXRepare Therapeutics11.50%UPXIUpexi31.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBDRXBiodexa Pharmaceuticals2036.54 million36.42 millionNot OptionableFBLGFibroBiologics1038.26 million30.61 millionN/ARPTXRepare Therapeutics18042.89 million37.96 millionOptionableUPXIUpexi13037.92 million25.93 millionOptionableUPXI, FBLG, RPTX, and BDRX HeadlinesRecent News About These CompaniesCantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to OverweightJune 18 at 1:23 AM | americanbankingnews.comSOL Drops Below $150 After Sell-Off Despite Growing Institutional Adoption NarrativeJune 17, 2025 | coindesk.comUpexi, Inc. CSO Brian Rudick to Speak at ICR Conference on Public Market Crypto StrategiesJune 17, 2025 | quiverquant.comUpexi's Chief Strategy Officer to Present at The ICR Conference Spotlight Series on June 20thJune 17, 2025 | globenewswire.comUpexi, Inc. (NASDAQ:UPXI) Sees Large Growth in Short InterestJune 17, 2025 | marketbeat.comCantor Fitzgerald Upgrades Upexi (NASDAQ:UPXI) to "Overweight"June 16, 2025 | marketbeat.comUpexi CEO and CSO to Host Fireside Chat on Thursday, June 26th at 11:00 a.m. ETJune 14, 2025 | seekingalpha.comUpexi (NASDAQ:UPXI) Shares Gap Up - Time to Buy?June 11, 2025 | marketbeat.comUpexi, Inc. Joins Webull Corporate Connect Service to Enhance Investor Engagement and CommunicationJune 11, 2025 | nasdaq.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comHODL On Tight: The Meteoric Rise of Crypto Treasury Companies – Downloadable ReportJune 10, 2025 | finance.yahoo.comUpexi Joins Webull Corporate Connect Service PlatformJune 9, 2025 | globenewswire.comUpexi options begin trading on Nasdaq marketJune 6, 2025 | investing.comUpexi Approved for Options Trading on NasdaqJune 5, 2025 | globenewswire.comWall Street Zen Upgrades Upexi (NASDAQ:UPXI) to HoldJune 2, 2025 | marketbeat.comUpexi, Inc. (NASDAQ:UPXI) Short Interest UpdateMay 31, 2025 | marketbeat.comUpexi to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference on June 24-25May 30, 2025 | globenewswire.comUpexi releases presentation detailing Solana treasury strategyMay 29, 2025 | finance.yahoo.comUpexi Partners with Crypto-Native Marketing and Design Firm, GMI Digital, to Drive Solana-Focused StrategyMay 29, 2025 | globenewswire.comUpexi, Inc. Acquires 77,879 Locked SOL for $11.8 Million, Increasing Holdings to 679,677 SOLMay 28, 2025 | quiverquant.comUpexi, Inc. Buys Additional Locked SOL at a Discount for $11.8 millionMay 28, 2025 | taiwannews.com.twNew MarketBeat Followers Over TimeMedia Sentiment Over TimeUPXI, FBLG, RPTX, and BDRX Company DescriptionsBiodexa Pharmaceuticals NASDAQ:BDRX$0.87 -0.16 (-15.87%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.86 0.00 (-0.40%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies for the treatment of diffuse intrinsic recurrent glioblastoma, diffuse midline glioma, and medulloblastoma; and MTD217, a program centered around a water-soluble drug formulation that can be easily infused or injected simultaneously, or sequentially, directly into the cancer microenvironment, currently under preclinical studies for the treatment of leptomeningeal disease. In addition, the company offers drug delivery platforms, such as Q-Sphera, a polymer microsphere microtechnology used for sustained release drug delivery; MidaSolve, an oligosaccharide nanotechnology used to solubilize drugs so that they can be administered in liquid form directly and locally into tumors; and MidaCore, a gold nanoparticle used for targeting sites of disease by using chemotherapeutic agents or immunotherapeutic agents. It has collaboration agreements with Janssen and Melior. The company was formerly known as Midatech Pharma plc and changed its name to Biodexa Pharmaceuticals Plc in March 2023. Biodexa Pharmaceuticals Plc was founded in 2000 and is headquartered in Cardiff, the United Kingdom.FibroBiologics NASDAQ:FBLG$0.70 -0.02 (-3.12%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$0.72 +0.02 (+3.51%) As of 06/20/2025 07:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.Repare Therapeutics NASDAQ:RPTX$1.41 0.00 (0.00%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.40 -0.01 (-1.06%) As of 06/20/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Upexi NASDAQ:UPXI$9.25 -1.54 (-14.27%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$9.54 +0.29 (+3.08%) As of 06/20/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Overheated Market? Analysts Watch These Red Flags Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
